Rupatadine Inhibits Proinflammatory Mediator Secretion from Human Mast Cells Triggered by Different Stimuli

Magdalini Vasiadi, Dimitris Kalogeromitros, Duraisamy Kempuraj, Anthony Clemons, Bodi Zhang, Caterina Chliva, Michael Makris, Adam Wolfberg, Michael House, Theoharis C. Theoharides

Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Pharmacology and Experimental Therapeutics, and Departments of Obstetrics and Gynecology, Internal Medicine and Biochemistry, Tufts University School of Medicine and Tufts Medical Center, Boston, Mass., USA; Allergy Clinical Research Center, Allergy Section, General Hospital Attikon, Athens University Medical School, Athens, Greece

Background: Mast cells are involved in allergy and inflammation by secreting multiple mediators including histamine, cytokines and platelet-activating factor. Certain histamine 1 receptor antagonists have been reported to inhibit histamine secretion, but the effect on cytokine release from human mast cells triggered by allergic and other stimuli is not well known. We investigated the ability of rupatadine, a potent histamine 1 receptor antagonist that also blocks platelet-activating factor actions, to also inhibit mast cell mediator release. Methods: Rupatadine (1–50 μM) was used before stimulation by: (1) interleukin (IL)-1 to induce IL-6 from human leukemic mast cells (HMC-1 cells), (2) substance P for histamine, IL-8 and vascular endothelial growth factor release from LAD2 cells, and (3) IgE/anti-IgE for cytokine release from human cord blood-derived cultured mast cells. Mediators were measured in the supernatant fluid by ELISA or by Milliplex microbead arrays. Results: Rupatadine (10–50 μM) inhibited IL-6 release (80% at 50 μM) from HMC-1 cells, whether added 10 min or 24 h prior to stimulation. Rupatadine (10–50 μM for 10 min) inhibited IL-8 (80%), vascular endothelial growth factor (73%) and histamine (88%) release from LAD2 cells, as well as IL-6, IL-8, IL-10, IL-13 and tumor necrosis factor release from human cord blood-derived cultured mast cells. Conclusion: Rupatadine can inhibit histamine and cytokine secretion from human mast cells in response to allergic, immune and neuropeptide triggers. These actions endow rupatadine with unique properties in treating allergic inflammation, especially perennial rhinitis and idiopathic urticaria.

Introduction

Mast cells are important effector cells in IgE-mediated allergic reactions, but also in immunity [1, 2] and inflammatory processes [3] due to their ability to secrete numerous vasoactive molecules and cytokines in response to a variety of stimuli. For instance, mast cells can secrete histamine, interleukin (IL)-6, IL-8, platelet-activating factor (PAF), tumor necrosis factor (TNF), tryptase and vascular endothelial growth factor (VEGF) [4]. IL-6 partici-
ponents in inflammation and acute-phase reactions [5], while IL-8 is a potent neutrophil chemotactic molecule [6], and VEGF also has vasodilatory actions [7]. In view of such findings, mast cells are now recognized to have a more critical role in diseases that may also involve inflammation, such as in asthma [8], but also in skin diseases [9].

Certain histamine 1 (H1) receptor antagonists have been reported to have variable antiallergic effects [10, 11]. Rupatadine is a newer H1 receptor antagonist [12, 13] with the ability to also inhibit actions of PAF [14, 15]. Rupatadine appears to be more potent than other antihistamines in the treatment of allergic rhinitis [16, 17] and chronic idiopathic urticaria [18–20]. We hypothesized that this apparent superior action might be due to, in addition to blocking PAF actions, the ability of rupatadine to inhibit the release of proinflammatory cytokines from mast cells.

Therefore, we examined the effect of rupatadine on human mast cell activation by 3 different triggers: (1) IL-1, which stimulates the release of IL-6 from human leukemic mast cells (HMC-1), (2) substance P (SP), which stimulates LAD2 human mast cells, to release histamine and cytokines, and (3) IgE/anti-IgE, which stimulates human umbilical cultured cord blood-derived mast cells (hCBMCs) to release histamine, IL-6, IL-8, IL-10, IL-13, TNF and VEGF. The present results indicate that rupatadine inhibits human mast cell activation by allergic and nonallergic triggers, effects that may explain its potent actions in rhinitis and chronic idiopathic urticaria.

Materials and Methods

Rupatadine was provided by Uriach, Inc., Barcelona, Spain. Rupatadine (1, 5, 10, and 25 µM) were prepared from stock (10^{-5} M) made as follows: 5.3 mg of rupatadine was diluted with 0.1 N HCl (5 drops) and 8 ml of distilled water; pH was adjusted to 5.0–5.5 with NaOH and the volume was adjusted to 10 ml. This stock solution was aliquoted and stored at –80 °C. Working dilutions were prepared in distilled water immediately before use.

Mast Cell Culture

HMC-1 [21] and LAD2 [22] cells were cultured for 5 and 14 days, respectively, as previously reported. Human umbilical cord blood was collected at Tufts Medical Center, Boston, Mass., USA, as approved by the Medical Center Human Investigation Review Board. Cord blood was diluted with Dulbecco’s phosphate-buffered saline (DPBS) from Gibco BRL (Life Technologies, Grand Island, N.Y., USA) containing 2 mM ethylenediaminetetraacetic acid (Sigma). Mononuclear cells were separated using Lymphocyte Separation Medium from Organon Teknika Corp., Durham, N.C., USA. CD34+ cells were isolated by positive selection of CD34+/AC133+ cells by magnetic associated cell sorting using an AC133+ cell isolation kit (Milleniy Biotec, Auburn, Calif., USA), as reported previously [23]. CD34+ cells were cultured in Iscove’s Modified Dulbecco’s Medium (Gibco BRL) containing 100 ng/ml recombinant human stem cell factor, 50 ng/ml IL-6 (Chemicon International, Inc., Temecula, Calif., USA), 5% fetal bovine serum (Biowhittaker, Walkersville, Md., USA), 5 × 10^{-5} M 2-mercaptoethanol, and 1% penicillin-streptomycin (Gibco BRL) for 4 weeks except during the last week for the Milliplex microbead assays; they were then cultured another 4 weeks in the same medium to which IL-4 (20 ng/ml; Chemicon International, Inc.) was added to increase maturation. During this culture period, the cells were washed with DPBS every week and resuspended using fresh complete culture medium. The purity of hCBMCs was evaluated by immunocytochemical staining for tryptase as previously described [23], and mast cell viability was determined by trypan blue (0.3%) exclusion; hCBMCs cultured for over 8 weeks were used in these experiments.

HMC-1 and LAD2 Cell Stimulation

HMC-1 cells (10^5 cells/condition) were preincubated with rupatadine for 10 min at the concentrations indicated, before stimulation with IL-1 (100 ng/ml) for 6 h at 37°C in 95%/5% CO2 atmosphere, as most cytokines are synthesized de novo [24]. For the time course experiments, rupatadine was added first at the doses and times indicated, and the cells were incubated until they were stimulated by the specific trigger. LAD2 cells (10^5 cells/condition for IL-8 assay, 5 × 10^4 cells/condition for VEGF, 3 × 10^4 cells/condition for histamine assay) were preincubated with rupatadine for 10 min at the concentrations indicated, before stimulation with SP (1 µM) for 24 h for IL-8 and VEGF release, and for 20 min for histamine release in human Tyrode’s buffer at 37°C in a shaking water bath. Control cells were treated with the same volume of culture medium/Tyrode’s buffer. IL-6, IL-8 and VEGF were measured in the supernatant fluid by ELISA (Quantikine, R&D Systems, Minneapolis, Minn., USA). Histamine levels in the supernatant fluid and pellet were measured fluorometrically using an LS-50B Luminescence Spectrometer (Perkin Elmer, Norwalk, Conn., USA) as reported previously [25]. Histamine release was expressed as percentage of the total cellular histamine content = ([histamine in supernatant)/(histamine in supernatant + histamine in pellet)] × 100.

Sensitization and Stimulation of hCBMCs

hCBMCs were washed with DPBS and plain culture medium once in each and resuspended in serum-free complete culture medium. Cells (10^6 cells/ml) were then incubated with human myeloma-IgE (2 µg/ml; Chemicon International, Inc.) at 37°C for 48 h in 24-well Falcon cell culture plates (Becton Dickinson, Franklin Lakes, N.J., USA). These sensitized hCBMCs (1.8 × 10^5 cells/condition) were incubated with rupatadine for 10 min at the concentrations indicated, before stimulation with anti-human IgE (10 µg/ml) for 24 h; supernatant fluid was then collected and analyzed for several mediators using Milliplex microbead arrays (Millipore, Billerica, Mass., USA).

HMC-1 and LAD2 cells do not respond to stimulation by IgE/anti-IgE while LAD2 cells do not produce IL-6; hence, IL-1 stimulation was used only with HMC-1 cells.
Statistics

Cytokine results are presented as actual amounts released since most cytokines are de novo synthesized and are not stored in the granules; in contrast, histamine is stored in the granules and can be measured in the cell pellet. Results from all samples testing inhibition were individually compared with the corresponding stimulated samples using the Student’s t test, as indicated in the legends, except for human results that were compared using the nonparametric Mann-Whitney U test. Data are represented as the mean ± SD. The level of statistical significance was set at p < 0.05.

Results

Effect of Rupatadine on IL-1 Stimulation of HMC-1 Cells

We had previously shown that IL-1 can stimulate HMC-1 cells to release only IL-6. Therefore, we tested the effect of rupatadine on IL-1 stimulation of HMC-1 cells. Rupatadine at 1, 5, 10, 25 and 50 μM added 10 min prior to IL-1 reduced IL-6 release from HMC-1 cells by 8, 20, 22, 54 and 77%, respectively (fig. 1). A preincubation time course showed that there was no difference whether rupatadine (10 μM) was added 10 min or 24 h prior to stimulation, but there was better inhibition when 25 μM was used for 60 min prior to stimulation (fig. 2). Spontaneous release and loss of cell viability were negligible at these rupatadine concentrations.

Effect of Rupatadine on SP Stimulation of LAD2 Cells

We then investigated the effect of rupatadine on LAD2 cells stimulated by SP. Rupatadine at 10, 25 and 50 μM added 10 min prior to SP (10 μM) inhibited IL-8 release from LAD2 cells by 40, 48 and 80%, respectively (fig. 3). We also compared the effect of rupatadine added together with or 10 and 60 min prior to SP. Rupatadine inhibited IL-8 release by 50% at 50 μM even when added together with SP (fig. 4). Although adding rupatadine 10

---

Fig. 1. Dose response of the inhibitory effect of rupatadine on IL-6 release from HMC-1 cells. HMC-1 cells were preincubated with rupatadine (Rup) for 10 min at 1, 5, 10, 25 and 50 μM and stimulated with IL-1 (100 ng/ml, for 6 h). Control mast cells were treated with culture medium only for 6 h. After the incubation period, the supernatant solution was collected and IL-6 was assayed by ELISA. Results were analyzed using the unpaired equal, 2-tailed, Student’s t test (n = 11). Spontaneous release was below the level of detection. * p < 0.05, significance of comparisons between conditions and samples treated with the trigger alone, as shown by the corresponding brackets.

Fig. 2. Time course of the inhibitory effect of rupatadine on IL-6 release from HMC-1 cells. HMC-1 cells were preincubated with rupatadine (RUP) at 10 and 25 μM for 10 min, 1, 6, 12 and 24 h and stimulated with IL-1 (at 100 ng/ml, for 6 h). Control mast cells were treated with culture medium only for 6 h. After the incubation period, the supernatant solution was collected and IL-6 was assayed by ELISA. Results were analyzed using the paired equal, 2-tailed, Student’s t test (n = 3). * p < 0.05, significance of comparisons between the results of the same concentration at different times of preincubation and 10 min of preincubation, as shown by the corresponding brackets.
Rupatadine Inhibits Human Mast Cell Activation

min prior to the trigger further reduced IL-8 release at all concentrations tested (fig. 4), there was no difference between 10- or 60-min preincubation.

Rupatadine at 5, 10 and 50 μM for 10 min prior to SP inhibited VEGF release by 18, 32 and 73%, respectively (fig. 5); histamine release was inhibited by 7, 13 and 88%, respectively (fig. 6).

**Effect of Rupatadine on IgE/Anti-IgE Stimulation of hCBMCs**

We then investigated the effect of rupatadine on stimulation of hCBMCs by IgE/anti-IgE. Rupatadine at 10 and 25 μM was added 10 min prior to stimulation with anti-IgE (10 μg/ml). Supernatant fluid was collected and analyzed for histamine fluorometrically, as well as for 37 molecules [IL-1α, IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17, IL-18, IL-23, VEGF, TNF-α, TNF-β, stem cell factor, interferon-γ, monocyte chemoattractant protein 1, macrophage inflammatory protein (MIP)-1, MIP-1α, MIP-2β, matrix metalloproteinase (MMP)-2, MMP-3, MMP-9, brain-derived neurotrophic factor, eotaxin, factor VII, granulocyte macrophage colony-stimulating factor, intercellular adhesion molecule 1, RANTES, interferon-γ and epidermal growth factor] using Milliplex microbead arrays.

IgE/anti-IgE stimulation significantly increased only IL-6 (fig. 7a), IL-8 (fig. 7b), IL-10 (fig. 7c), IL-13 (fig. 7d) and TNF release (fig. 7e); VEGF results were too variable. Rupatadine at 25 μM reduced IL-6 release from 715 ± 865.8 pg/ml after anti-IgE to 364 ± 36.4 pg/ml (69% inhibition, p = 0.0012), IL-8 release from 5,120 ± 934.9 to 2,012 ± 29.4 pg/ml (63% inhibition, p = 0.0045), IL-10 release from 86 ± 16.8 to 30 ± 4.9 pg/ml (34% inhibition,
p = 0.005), IL-13 release from 188 ± 3.3 to 48 ± 3.4 pg/ml (79% inhibition, p = 0.00000001), and TNF release from 107 ± 15.3 to 56 ± 4.5 pg/ml (55% inhibition, p = 0.0055), as shown in figure 7.

**Discussion**

In the present paper, we investigated stimulation of human mast cells by different triggers. HMC-1 mast cells were stimulated by IL-1, which we had previously shown to release only IL-6 [24]; HMC-1 cells were also used because they grow rapidly in culture allowing us to carry out both dose-response and time-course experiments. We did not use IL-1 stimulation with LAD2 cells because these cells do not secrete IL-6. Instead, we stimulated LAD2 cells with the neuropeptide SP [3], to which HMC-1 cells do not respond, and measured the most abundant mediators produced, histamine, IL-8 and VEGF. Finally, we stimulated primary cultured human mast cells (hCBMCs), which grow slowly and are not as plentiful, with IgE/anti-IgE and measured a number of mediators. It is obvious from the above that the same stimuli could not be compared in all these types of human mast cells. The present results indicate that rupatadine can inhibit the secretion of histamine and the proinflammatory mediators IL-6, IL-8, IL-10, IL-13, TNF and VEGF from human mast cells, stimulated by allergic and other triggers.

The inhibitory action of rupatadine did not exhibit a classic dose-response curve, as it was limited to within 1 log (5–50 μM). The IC50 for the inhibitory effect of rupatadine on human mast cell secretion was about 25 μM, within the range previously reported for rupatadine’s inhibition of histamine and TNF release from canine skin mast cells [26]. This concentration is 250–1,000 times higher than the concentration required for H1 receptor antagonism depending on the assays used [12]. Even though rupatadine is marketed as 10 mg/day, it is increasingly used by clinicians at 20 mg/day for chronic
idiopathic urticaria [18]. The rupatadine plasma concentration achieved with a single 20 mg/day in humans is $C_{\text{max}} = 4.3 \mu g/l$ [27]. Assuming this $C_{\text{max}}$ and the molecular weight of rupatadine (fumarate salt) to be 415.96, the plasma concentration is approximately 0.01 $\mu M$. Primary mast cells in the nose or skin may be more sensitive to the action of rupatadine than cultured mast cells, to be tested in the future with ex vivo treatment of nasal polyp or skin biopsies from patients. In addition, much higher rupatadine local concentrations could be achieved after instilla-

Fig. 7. Effect of rupatadine (25 $\mu$M for 10 min) on IL-6 (a), IL-8 (b), IL-10 (c), IL-13 (d) and TNF release (e) release from hCBMCs measured by Milliplex microbead array (n = 3). Data were analyzed by the unpaired equal, 2-tailed, Student’s t test. * $p < 0.05$, significance of comparisons between conditions and samples treated with the trigger alone, as shown by the corresponding brackets.
tion into the nasal mucosa of a topical rupatadine solution. For instance, topical application into a nostril of 150 μl of 1 mg/ml rupatadine solution (feasible) means 150 μg rupatadine that could produce a local concentration closer to the values used in this study. Other H1 receptor antagonists had previously been shown to inhibit mast cell granule-stored mediators in similar concentrations to what we report here for rupatadine [10, 11]. For instance, azelastine resulted in a maximal inhibition of tryptase (55%) and histamine (41%) release [28], as well as of IL-6 (83%) release from hCBMCs at 24 μM [25]. Azelastine also inhibited IL-6, IL-8 and TNF release from hCBMCs stimulated by IgE/anti-IgE [29]. More recently, the H1 receptor antagonists [30] epinastine (40 μM) and azelastine (200 μM) reduced IL-8 release by almost 30%, epinastine and olopatadine reduced IL-10 release by 30–50%, while epinastine and olopatadine reduced TNF release by about 30% [30]. However, as we also observed with rupatadine, there was no clear dose-response effect [30], and the extent of inhibition also varied considerably, with epinastine showing the strongest inhibition of IL-8 and IL-10, while azelastine was the most potent inhibitor for TNF. In contrast, rupatadine inhibited the release of all these cytokines (IL-8, IL-10, TNF) at 25–50 μM. However, no comparative studies with other antihistamines were performed.

Mast cell activation by IgE has traditionally relied on the measurement of preformed mast cell mediators, such as histamine, which is stored in the secretory granules [31–33]. It is now recognized that human mast cells produce a number of cytokines, most of which are newly synthesized upon activation [34]. However, there is considerable heterogeneity on the cytokine content of various human cell types [34–37], making it necessary to measure different mediators from different types of mast cells in different pathophysiological settings. Moreover, mast cells can secrete cytokines selectively, without degranulation [38]. In particular, we had shown that IL-1 can stimulate selective release of IL-6 [24], while corticotropin-releasing hormone can release VEGF selectively without degranulation [39].

The mechanism of the inhibitory action of rupatadine is not known at present. The H1 receptor is not likely to be involved as rupatadine can effectively antagonize this receptor at <0.1 nM, while >10 μM are required for mast cell inhibition. Moreover, pretreatment of mast cells with diphenhydramine (50 μM), which totally blocks the H1 receptor, could not prevent the ability of rupatadine to inhibit mast cells (results not shown). Rupatadine may inhibit intracellular calcium ion elevations and/or nuclear factor-κB activation, as previously shown for azelastine [29]. The ability of rupatadine to antagonize PAF may also somehow contribute to mast cell inhibition, especially if PAF is secreted from mast cells and has an autocrine stimulatory action.

**Conclusion**

Rupatadine is a potent H1 receptor antagonist with additional anti-PAF and mast cell secretion blocking effects. These properties could be particularly useful in the treatment of allergic inflammation present in a variety of airway and skin diseases, such as perennial rhinitis and chronic idiopathic urticaria, both of which are fairly resistant to common H1 receptor antagonists. However, the present studies did not use primary mast cells from the respective tissues and, therefore, cannot be directly extrapolated to the clinical settings.

**Acknowledgments**

We thank Uriach, Inc., Barcelona, Spain, for providing rupatadine and for partially funding this study, as well as Amgen, Inc., Thousand Oaks, Calif., USA, for their generous gift of recombinant human stem cell factor. We also thank Millipore Inc., Billerica, Mass., USA, for performing the Luminex microbead array analysis, as well as Dr. Butterfield (Mayo Clinic, Rochester, Minn., USA) for providing the HMC-1 cells, and Drs. D. Metcalfe and A.S. Kirshenbaum (NIH, Bethesda, Md., USA) for providing the LAD2 mast cells. We also thank the personnel of the Maternal-Fetal Division of Tufts Medical Center for collecting the umbilical cord blood used in these studies.

**Disclosure**

US patents No. 6624148, 6689748, 6984667, 7115278, 10/811825 and EPO 136577 (awarded to T.C.T.) cover the use of methods and compositions of mast cell blockers, including the combination of H1 receptor antagonists (and rupatadine specifically) together with flavonoids and proteoglycans in allergic and inflammatory diseases.

**References**


Rupatadine Inhibits Human Mast Cell Activation

Int Arch Allergy Immunol 2010;151:38–45


